Physician profile
Darin Busby
NPI 1831651405
$5,143.10
in general payments reported to CMS, 2019-2025
23 companies · $2,645 in 2025
The $2,645 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $124 · 2022: $672 · 2023: $704 · 2024: $998 · 2025: $2,645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,211 · Grant: $2,000 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,211.10 |
| Grant | $2,000.00 |
| Education | $135.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,018.09 | 2023-2025 | Cobalt Dr Mri Surescan |
| Boston Scientific Corporation | $452.70 | 2022-2025 | Farapulse, Watchman Access System, Latitude Communicator Power Supply |
| Astrazeneca Pharmaceuticals LP | $450.07 | 2022-2025 | Wainua, Farxiga, Brilinta |
| Abiomed | $404.02 | 2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.15 | 2022-2023 | Jardiance |
| Pfizer INC. | $162.13 | 2022-2024 | |
| Abbott Laboratories | $160.26 | 2024-2025 | Ensite, Cardiomems |
| Penumbra, INC. | $143.00 | 2025 | Indigo System |
| E.R. Squibb & Sons, L.L.C. | $131.15 | 2022-2024 | Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.74 | 2021 | |
| Irhythm Technologies, INC. | $122.42 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Philips North America LLC | $113.43 | 2024 | (Bh4) Igt Devices Undivided |
| Novartis Pharmaceuticals Corporation | $106.63 | 2024-2025 | |
| Amgen INC. | $104.01 | 2022-2023 | Repatha |
| Shockwave Medical, INC | $91.56 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $74.32 | 2022-2025 | Winrevair |
| Novo Nordisk INC | $36.91 | 2022-2023 | |
| United Therapeutics Corporation | $34.86 | 2025 | Tyvaso |
| Janssen Pharmaceuticals, INC | $33.39 | 2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $27.38 | 2025 | Amvuttra |
| Bridgebio Pharma, INC. | $20.07 | 2025 | Attruby |
| Livanova USA, INC. | $14.88 | 2022 | |
| Edwards Lifesciences Corporation | $13.93 | 2024 | Sapien 3 Ultra Resilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darin Busby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.